Ernexa Therapeutics (ERNA) Common Equity (2016 - 2025)
Historic Common Equity for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $3.6 million.
- Ernexa Therapeutics' Common Equity rose 10786.46% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 10786.46%. This contributed to the annual value of $1.7 million for FY2024, which is 2382.45% down from last year.
- Latest data reveals that Ernexa Therapeutics reported Common Equity of $3.6 million as of Q3 2025, which was up 10786.46% from $4.4 million recorded in Q2 2025.
- In the past 5 years, Ernexa Therapeutics' Common Equity ranged from a high of $53.6 million in Q2 2021 and a low of -$45.4 million during Q3 2024
- Its 5-year average for Common Equity is $6.4 million, with a median of $4.2 million in 2023.
- Its Common Equity has fluctuated over the past 5 years, first soared by 35579.91% in 2021, then crashed by 137436.83% in 2024.
- Ernexa Therapeutics' Common Equity (Quarter) stood at $31.5 million in 2021, then plummeted by 61.6% to $12.1 million in 2022, then tumbled by 81.56% to $2.2 million in 2023, then dropped by 23.82% to $1.7 million in 2024, then soared by 109.88% to $3.6 million in 2025.
- Its Common Equity stands at $3.6 million for Q3 2025, versus $4.4 million for Q2 2025 and -$5.9 million for Q1 2025.